Table 2. Characteristics of Men With Localized Prostate Cancer in High-Use and Low-Use Primary ADT Health Service Areasa.
| Characteristic | Cancer Grade | |||||
|---|---|---|---|---|---|---|
| Moderately Differentiated | Poorly Differentiated | All Localized | ||||
| High Use (n = 16 358) | Low Use (n = 13 480) | High Use (n = 7452) | Low Use (n = 7220) | High Use (n = 23 319) | Low Use (n = 22 302) | |
| Primary ADT within 180 d | 6345 (38.8) | 3008 (22.3) | 4748 (63.7) | 3462 (48.0) | 10 881 (46.7) | 6553 (29.4) |
| Primary ADT within 18 mo | 7582 (46.4) | 3894 (28.9) | 5539 (74.3) | 4188 (58.0) | 12 868 (55.2) | 8250 (37.0) |
| Duration of primary ADT use, mean (SD), mo | 53 (43) | 49 (43) | 44 (33) | 39 (33) | 49 (39) | 46 (40) |
| Age at diagnosis, median (IQR), y | 77 (73-81) | 77 (72-81) | 80 (75-84) | 79 (74-84) | 78 (73-82) | 77 (73-82) |
| Zip code level income, median (IQR), US $ | 44 099 (33 965-60 591) | 46 002 (35 792-57 418) | 43 074 (34 041-60 646) | 43 034 (32 466-54 229) | 43 994 (34 226-61 026) | 44 909 (34 655-56 912) |
| Charlson score, %b,c | ||||||
| 0 | 10 406 (63.6) | 9542 (70.8) | 4664 (62.6) | 4520 (62.6) | 14 889 (63.8) | 15 550 (69.7) |
| 1 | 3633 (22.2) | 2514 (18.6) | 1622 (21.8) | 1587 (22.0) | 5104 (21.9) | 4299 (19.3) |
| ≥2 | 2319 (14.2) | 1424 (10.6) | 1166 (15.6) | 1113 (15.4) | 3326 (14.3) | 2453 (11.0) |
| Clinical stage Tla | 7671 (46.9) | 6142 (45.6) | 3099 (41.6) | 2680 (37.1) | 11 269 (48.3) | 9836 (44.1) |
| PSA, ng/mL, meanc | 9.7 (0.2) | 9.3 (0.2) | 20.4 (0.5) | 18.0 (0.4) | 14.8 (0.2) | 13.9 (0.2) |
| Gleason score, %c | ||||||
| 2-6 | 5105 (31.2) | 4774 (35.4) | NA | NA | 5043 (21.6) | 4496 (20.2) |
| 7 | NA | NA | 2502 (33.6) | 2692 (37.3) | 2846 (12.2) | 2586 (11.6) |
| ≥8 | NA | NA | 1517 (20.4) | 1450 (20.1) | 1695 (7.3) | 1417 (6.4) |
Abbreviations: ADT, androgen-deprivation therapy; IQR, interquartile range; NA, not applicable; PSA, prostate-specific antigen.
a
Data are given as number (percentage).
b
See Table 1 for explanations of Charlson score and clinical stage tumor (T1).
c
The PSA values and Gleason scores were based on patients diagnosed in 2004 or thereafter.